- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01909505
Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men
July 24, 2013 updated by: Saliva Biomarkers, Inc.
Comparison of Salivary Testosterone With Serum Free Testosterone Done by Equilibrium Dialysis.
Low testosterone is a common male problem.
The diagnosis of low testosterone often requires blood sampling and expensive testing.
We want to know if measuring saliva testosterone can be used in place of blood sampling.
Study participants will be asked to provide samples of blood and saliva for the measurement of testosterone.
These results may lead to the development of a saliva test for testosterone.
Study Overview
Status
Unknown
Conditions
Detailed Description
Testosterone is required for normal male health that is known to decline in aging or other conditions.
Physiologically active testosterone, also known as "free" testosterone, is present as a small percentage of the total blood level, mostly bound to sex hormone binding globulin and albumin.
Estimation of serum free testosterone is difficult and costly, requiring equilibrium dialysis of a serum sample.
These binding proteins are not normally present in saliva.
It is hypothesized that the free fraction of testosterone in blood is in equilibrium with the extravascular space, notably saliva.
The sponsor proposes to test this hypothesis by sampling saliva and serum and measuring testosterone.
Serum free testosterone will be measured following equilibrium dialysis.
To perform this study approximately 40 eugonadal and 20 hypogonadal males will be recruited.
Study Type
Observational
Enrollment (Anticipated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Recruiting
- Georgetown University Medical Center
-
Contact:
- Amber Surian
- Phone Number: 202-444-1210
- Email: aas64@georgetown.edu
-
Principal Investigator:
- West T Moore, M.D.
-
-
Maryland
-
Baltimore, Maryland, United States, 21827
- Recruiting
- John's Hopkins University Medical Center
-
Contact:
- Ernest Evans
- Phone Number: 410-955-2812
- Email: eevans21@jhmi.edu
-
Principal Investigator:
- Adrian Dobbs, M.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Forty normal males and 20 male subjects, 25 to 65 years of age.
Description
Inclusion Criteria:
- Normal male subjects aged 20-65 years
Exclusion Criteria:
- Women Smokers, HIV positive, diabetes, hepatatis C positive, subjects currently taking testosterone who are unwilling to suspend use for teh duration of the trial, subjects taking aldactone or medicines that may interfere with the protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
|---|
|
Normal Males
Males with normal levels of serum testosterone
|
|
Hypogonadal males
Males known to have low levels of serum testosterone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood and saliva testosterone
Time Frame: 1 year
|
Measures of blood and saliva testosterone
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: West T Moore, M.D., Georgetown University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Anticipated)
June 1, 2014
Study Completion (Anticipated)
July 1, 2014
Study Registration Dates
First Submitted
July 24, 2013
First Submitted That Met QC Criteria
July 24, 2013
First Posted (Estimate)
July 26, 2013
Study Record Updates
Last Update Posted (Estimate)
July 26, 2013
Last Update Submitted That Met QC Criteria
July 24, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Other Study ID Numbers
- Saliva Testosterone
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Known Androgen Deficiency
-
GlaxoSmithKlineCompletedHealthy Subjects | Androgen DeficiencyUnited States
-
Neon HospitalCompletedOcular Surface Disease | Androgen Deficiency | Tear OsmolarityTurkey (Türkiye)
-
HealthCore-NERIBayer; Besins HealthcareCompletedMale Hypogonadism | Testosterone Deficiency | Androgen DeficiencyItaly, United Kingdom, Spain, Netherlands, Germany, Sweden
-
Neon HospitalCompletedEffects of the External Testosteron Intake Over the Choroids of the Patients With Androgen DeficiencyTurkey
-
Oxford University Hospitals NHS TrustWithdrawnKnown Difficult IntubationUnited Kingdom
-
University of California, San FranciscoGeneral ElectricCompletedKnown or Suspected Abdominal DiseaseUnited States
-
University Hospital Inselspital, BerneUniversity of Zurich; University Hospital MuensterCompletedPolymorphism, Genetic | Libido | Receptors, Androgen | Androgen EffectSwitzerland
-
GE HealthcareRecruitingKnown or Highly Suspected Central Nervous System (CNS) Lesion | Known or Highly Suspected Body (Excluding CNS) LesionUnited States, Georgia, Moldova
-
Jan FrystykRecruitingHeart Failure | Cardiovascular Morbidity | Androgen DeficiencyDenmark
-
BayerCompleted